{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3892","value":"116.2"},{"comment":"Geometric mean and geometric coefficient of variation could not be estimated as only 2 observations were above lower limit of quantification and individual value were 6100 and 6100 nanograms per milliliter.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"title":"Encorafenib: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"180","value":"10.44"},{"groupId":"OG001","spread":"229","value":"15.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"title":"Encorafenib: Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"137","value":"10.60"},{"groupId":"OG001","spread":"179","value":"13.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"Encorafenib: Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"193","value":"9.926"},{"groupId":"OG001","spread":"169","value":"17.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"title":"Encorafenib: Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"217","value":"10.02"},{"groupId":"OG001","spread":"201","value":"17.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"title":"Encorafenib: Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"169","value":"11.74"},{"groupId":"OG001","spread":"143","value":"15.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"title":"Encorafenib: Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"549","value":"35.54"},{"comment":"Geometric mean and geometric coefficient of variation could not be estimated as only 1 observation was above lower limit of quantification and individual value was 239 nanograms per milliliter.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"title":"LHY746: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"251","value":"44.71"},{"groupId":"OG001","spread":"213","value":"62.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"title":"LHY746: Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"178","value":"50.36"},{"groupId":"OG001","spread":"220","value":"61.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"LHY746: Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"224","value":"41.61"},{"groupId":"OG001","spread":"205","value":"76.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"title":"LHY746: Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"242","value":"37.87"},{"groupId":"OG001","spread":"192","value":"66.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"title":"LHY746: Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"250","value":"58.59"},{"groupId":"OG001","spread":"212","value":"72.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"title":"LHY746: Cycle 6 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"description":"Trough plasma concentration of encorafenib and its metabolite LHY746 was measured in this outcome measure.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"Phase 3: Arm A [EC]"},{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG001","title":"Phase 3: Arm B [EC + mFOLFOX6]"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK concentration set was defined as all enrolled participants who were treated and had at least 1 analyte concentration. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. Here, \"Number Analyzed\" signifies participants evaluable at specified timepoints. Participants received encorafenib in Arms A and B of Phase 3, hence data is reported only for Arms A and B and not for Arm C.","reportingStatus":"POSTED","timeFrame":"Predose on Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1 and Cycle 6 Day 1","title":"Phase 3: Trough Plasma Concentration of Encorafenib and Its Metabolite LHY746","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}